Skip to content

Targeted Oncology:

Biologically Validated. Chemistry Enabled. Albumin Protected.

Exploiting metabolic pathways to target tumors with effective therapeutics.

Our initial development programs are focused on oncology, specifically related to therapeutics.

About Us

Our Product Strategy

January Therapeutics is targeting cell-essential drivers of cancer which cannot be successfully drugged by chemistry alone. January’s technology exploits the dysregulated metabolic pathways in cancer and uses albumin to preferentially deliver drug to tumors while sparing healthy cells.

Thomas B. Broudy, PhD

CEO

News and Events

Some recent milestones

Partnerships

January Therapeutics is growing world class partnerships across academia and industry.

We are working together to create better medicines and create the next generation of albumin-enabled drug delivery.

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Contact

Get in touch

11575 Sorrento Valley Road, Suite 212
San Diego, California 92121

Lorem ipsum

consectetur adipiscing elit

John Smith

Sample Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod te mpor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel fa cilisis commodo viverra.

Copyright © 2021 January Therapeutics – All Rights Reserved.

About Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

About City of Hope

City of Hope’s mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. As an independent, National Cancer Institute-designated comprehensive cancer center, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. Research and technology developed at City of Hope has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. A leader in bone marrow transplantation and immunotherapy, such as CAR T cell therapy, City of Hope’s personalized treatment protocols help advance cancer care throughout the world. 

With a goal of expanding access to the latest discoveries and leading-edge care to more patients, families and communities, City of Hope’s growing national system includes its main Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, scheduled to open in 2022, and Cancer Treatment Centers of America. City of Hope’s affiliated family of organizations includes Translational Genomics Research Institute and AccessHope. For more information about City of Hope, follow us on FacebookTwitterYouTubeInstagram and LinkedIn.